{"title":"The prevention of secondary stroke, cardiac outcomes and cognitive decline in patients with cerebrovascular disease: The PROGRESS trial","authors":"Neil Chapman , John Chalmers","doi":"10.1053/j.scds.2003.00.027","DOIUrl":null,"url":null,"abstract":"<div><p>Individuals with a history of cerebrovascular disease have elevated risks of recurrent stroke, other cardiovascular events, and cognitive decline. In the Perindopril Protection Against Recurrent Stroke Study, 6,105 hypertensive and nonhypertensive individuals with a history of stroke or transient ischemic attack were randomly assigned active blood-pressure-lowering treatment (a flexible regimen that included perindopril and indapamide) or placebo. Over a mean follow-up period of 3.9 years, active treatment lowered the relative risks of stroke by 28%, major vascular events, major coronary events, and congestive heart failure each by 26%, and cognitive decline by 19%. The benefits observed were similar in those both with and without hypertension at baseline.</p></div>","PeriodicalId":101154,"journal":{"name":"Seminars in Cerebrovascular Diseases and Stroke","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2003-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1053/j.scds.2003.00.027","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Cerebrovascular Diseases and Stroke","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1528993103800298","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Individuals with a history of cerebrovascular disease have elevated risks of recurrent stroke, other cardiovascular events, and cognitive decline. In the Perindopril Protection Against Recurrent Stroke Study, 6,105 hypertensive and nonhypertensive individuals with a history of stroke or transient ischemic attack were randomly assigned active blood-pressure-lowering treatment (a flexible regimen that included perindopril and indapamide) or placebo. Over a mean follow-up period of 3.9 years, active treatment lowered the relative risks of stroke by 28%, major vascular events, major coronary events, and congestive heart failure each by 26%, and cognitive decline by 19%. The benefits observed were similar in those both with and without hypertension at baseline.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
